Genmab A/S (GMAB) Set to Release Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Genmab A/S to announce earnings of $0.36 per share and revenue of $1.20 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, analysts expect Genmab A/S to post $1.22 EPS for the current fiscal year and $1.70 EPS for the next fiscal year.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $55.52 on Wednesday. The company has a market cap of $34.65 billion, a PE ratio of 39.51, a price-to-earnings-growth ratio of 2.20 and a beta of 0.73. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company has a 50-day simple moving average of $38.00 and a 200-day simple moving average of $30.79.

Analyst Ratings Changes

A number of brokerages recently issued reports on GMAB. TD Cowen raised their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Morgan Stanley boosted their price target on Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. New Street Research set a $43.00 price target on Genmab A/S in a research note on Wednesday, July 22nd. Finally, Truist Financial reissued a “buy” rating and set a $67.00 price target (up from $45.00) on shares of Genmab A/S in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.